Does MRA Use Contrast? What to Know Before Your Scan

MRA, or magnetic resonance angiography, does not always require contrast. Many MRA exams are performed entirely without injecting anything into your veins, relying instead on the natural movement of blood to generate images of your arteries and veins. When contrast is used, it is a gadolinium-based agent rather than the iodine-based dye used in CT scans, and the choice between contrast and no contrast depends on which blood vessels your doctor needs to see, how much detail is required, and your kidney function. Understanding the difference matters because it affects both what you will experience during the scan and the small but real safety considerations involved.

When MRA Skips Contrast Entirely

A significant share of MRA studies are done without any contrast injection at all. Non-contrast MRA takes advantage of a simple fact: blood is moving, and the surrounding tissue is not. The MRI scanner can be programmed to detect that motion and use it to create bright images of blood vessels against a dark background. The most common version of this, called time-of-flight MRA, is a workhorse technique for imaging arteries in the head and neck. It works well enough in those locations that many radiologists consider it the default starting point, with no injection needed.

Non-contrast techniques have expanded well beyond the brain. Newer methods use the heart’s own rhythm to time image acquisition, gating the scan to the cardiac cycle so that images capture arteries when blood flow is at its peak. These approaches have become increasingly useful for imaging blood vessels in the chest, abdomen, pelvis, and legs, and they are especially valuable for people who cannot safely receive gadolinium, including those with severe kidney disease, pregnant women, and children.¹ The tradeoff is that non-contrast scans tend to take longer and can be more sensitive to patient movement, which sometimes means slightly lower image quality compared to a contrast-enhanced exam.

Why Contrast Is Sometimes Added

When your radiologist does decide to use contrast for MRA, the injected agent is gadolinium-based. Gadolinium is a rare-earth metal that, when chelated (locked inside a protective molecular cage), makes blood vessels light up brightly on MRI by changing how nearby water molecules behave in the magnetic field.² The injection is typically given through a small IV in your arm, and the scan is timed so that images are captured during the brief window when the gadolinium is flowing through the vessels of interest.

Contrast-enhanced MRA tends to outperform non-contrast versions when very fine detail matters or when the vessels being imaged are deep in the body. A meta-analysis comparing the two approaches for detecting narrowing of the renal arteries found that gadolinium-enhanced MRA had both higher sensitivity (about 97%) and significantly better specificity (93%) than non-enhanced MRA, which came in at 94% sensitivity and 85% specificity.³ That gap in specificity is the practical difference: without contrast, MRA is more likely to flag a normal artery as narrowed, which can lead to unnecessary follow-up testing.

For imaging the aorta and iliac arteries before vascular surgery, contrast-enhanced MRA has shown accuracy above 94% when compared against traditional catheter angiography, and in most cases it provided enough information to plan the procedure without needing an invasive catheter study at all.⁴ In the arteries of the lower leg, the picture is more nuanced. One study comparing both approaches in patients with peripheral artery disease found that contrast-enhanced MRA produced “good” image quality in about 76% of vessel segments, versus 65% for non-contrast MRA. But the non-contrast version actually had slightly higher sensitivity for catching significant blockages (96% versus 90%), even though it was less specific.⁵ The bottom line is that contrast doesn’t universally make MRA better; it makes it better in specific situations.

Gadolinium Safety and Your Kidneys

If your doctor orders a contrast-enhanced MRA, the first thing the radiology team will want to know is how well your kidneys work. That concern traces back to a condition called nephrogenic systemic fibrosis (NSF), a rare but serious disease involving thickening and hardening of the skin and connective tissue that was linked to certain older gadolinium agents in people with severe kidney impairment. The discovery led to a wholesale shift in which gadolinium formulations are used and in whom.

Modern gadolinium agents fall into two broad chemical categories: macrocyclic (where the gadolinium ion sits inside a cage-like molecule) and linear (where it sits in an open chain). The older linear agents were the ones most strongly linked to NSF, and most have been pulled from markets or restricted. The macrocyclic and newer linear agents classified as “Group II” by the American College of Radiology appear to carry dramatically lower risk. A systematic review pooling nearly 5,000 patients with stage 4 or 5 kidney disease who received Group II agents found zero cases of NSF, placing the upper bound of risk below about 0.07%.⁶

A large real-world database study reinforced that finding, showing that the rate of diagnostic codes suggesting possible NSF in patients with advanced kidney disease who received contemporary gadolinium agents was no higher than in matched controls without kidney problems.⁷ This does not mean gadolinium is risk-free for people with impaired kidneys, but it does mean that if your doctor recommends contrast-enhanced MRA and chooses a modern agent, the specific fear of NSF is very small. Many radiology departments still check kidney function with a blood test before administering gadolinium, especially if you have diabetes, a history of kidney disease, or are over 60.

Gadolinium Retention in the Body

Even if your kidneys work perfectly, a small amount of gadolinium stays behind after the bulk of the contrast agent is flushed out through your urine. Most of the injected dose leaves the body within hours, primarily through the kidneys.⁸ But tiny traces can be detected in brain tissue, bone, and skin weeks or months later, and the amount retained differs sharply depending on the type of agent used.

Linear gadolinium agents release their gadolinium ion more easily than macrocyclic ones, which hold the metal more tightly inside that cage-like structure. Animal studies have shown that after repeated injections, linear agents leave behind substantially more gadolinium in brain structures than macrocyclic agents do. In one rat study, gadolinium concentrations in a specific brain region were roughly 19 times higher after repeated doses of a linear agent (gadodiamide) compared to a macrocyclic agent (gadoterate).⁹ Human tissue studies have confirmed a similar pattern: one comparison of a linear and a macrocyclic agent found that the linear agent left behind three to more than six times as much gadolinium in the brain, and over four times as much in bone.¹⁰

Whether this retained gadolinium causes any health problems remains genuinely uncertain. Bright spots on follow-up brain MRIs in people who have had many contrast-enhanced scans are well documented, but large studies have not linked these to neurological symptoms or cognitive decline. Still, the uncertainty has pushed most radiology departments toward using macrocyclic agents as their default, and the European Medicines Agency went further by suspending the marketing authorizations for several intravenous linear agents altogether. If you are someone who will need repeated MRA exams over your lifetime, such as for monitoring a brain aneurysm, this is worth asking about.

Allergic Reactions to Gadolinium

Allergic-type reactions to gadolinium contrast are uncommon but not unheard of. The vast majority are mild: a brief bout of hives, a warm or flushed feeling, or a metallic taste in the mouth during the injection. Serious anaphylactic reactions are rare, and fatal ones are extremely rare, though case reports exist.¹¹

The risk is not identical across all gadolinium agents. A large study drawing on global adverse-event databases found that all gadolinium-based contrast agents can trigger hypersensitivity reactions, but the pattern varies by product. Some agents showed higher reporting rates for anaphylactic or anaphylactoid shock, while others were more associated with angioedema or severe skin reactions.¹² If you have had a prior reaction to a gadolinium agent, tell your radiology team before the scan. They can pre-medicate you with antihistamines and steroids, switch to a different gadolinium product, or recommend a non-contrast approach instead.

How MRA Compares to CT Angiography

If your doctor is ordering a scan to look at your blood vessels, MRA is not the only option. CT angiography (CTA) is the main competitor, and the two technologies have different strengths. CTA is faster, often taking only a few seconds of active scanning, and produces very sharp images of large arteries. It uses iodine-based contrast and exposes you to ionizing radiation, both of which MRA avoids. MRA’s lack of radiation is a meaningful advantage for younger patients and anyone who will need repeat imaging over time.

Diagnostically, the two are often close. A review comparing MRI/MRA and CTA for detecting dissections in the carotid and vertebral arteries found their test performance characteristics to be relatively similar overall.¹³ A head-to-head study with direct comparison did find that CTA identified more specific features like intimal flaps and pseudoaneurysms, with a significant preference for CTA when imaging the vertebral arteries in particular.¹⁴ MRA, on the other hand, tends to excel at showing the vessel wall itself (useful for detecting early disease) and is especially valuable for imaging small arteries and veins.¹⁵

The practical decision often comes down to context. In an emergency, CTA wins because it is fast and widely available. For planned surveillance of a known vascular condition, MRA is often preferred because it avoids radiation and can frequently be done without contrast. If you have kidney disease that rules out both iodine contrast and gadolinium, non-contrast MRA may be the only vascular imaging option left on the table.

Artifacts and Limitations of Non-Contrast MRA

Non-contrast MRA has a well-known quirk that trips up both patients and clinicians: the flow void artifact. In time-of-flight MRA, blood needs to be flowing at a steady pace to show up as bright. When blood passes through a tight narrowing, it speeds up and becomes turbulent, and the MRA signal can drop out entirely, creating a gap in the image that looks like a complete blockage even when the vessel is still open. One study of carotid artery imaging found flow voids in about 16% of arteries scanned with time-of-flight MRA. Among those, the positive predictive value for severe stenosis was about 84%, meaning roughly one in six flow voids was misleading.¹⁶ This is one reason radiologists sometimes follow up a non-contrast MRA with a contrast-enhanced study or a different modality when a flow void appears in a critical location.

Contrast-enhanced MRA largely sidesteps this problem because the gadolinium brightens blood regardless of flow direction or turbulence. But it introduces its own timing challenge: the contrast bolus passes through the arteries in seconds, so the scan has to be triggered precisely. If the timing is off, nearby veins may fill with contrast and overlap the arteries, muddying the picture. Experienced technologists rarely miss the window, but it is one reason some centers use automated bolus-detection software.

Ferumoxytol as an Alternative Contrast Agent

For patients who cannot receive gadolinium at all, an iron-based contrast agent called ferumoxytol has emerged as an off-label alternative. Ferumoxytol was originally approved as an intravenous iron-replacement therapy for anemia in people with chronic kidney disease, but radiologists discovered that it also makes blood vessels light up on MRI. Because it contains no gadolinium, it carries no risk of NSF.¹⁷

One practical advantage of ferumoxytol is that it stays in the bloodstream much longer than gadolinium agents, which are cleared within minutes. That prolonged vascular signal gives radiologists a wider time window to acquire images, which is helpful for complex studies that require multiple sequences or cover large areas of the body.¹⁸ Dose-finding studies have explored optimal amounts for patients with chronic kidney disease.¹⁹ Ferumoxytol is not without its own risks, including rare but serious allergic reactions, and its use as an MRI contrast agent is considered off-label in the United States. Still, for patients with advanced kidney disease who need contrast-enhanced vascular imaging, it fills a gap that no gadolinium agent safely can.

Special Situations for Children and Pregnancy

Children and pregnant women represent two groups where the contrast question gets particularly careful thought. For children, the good news is that gadolinium contrast agents have a strong safety track record in pediatric use. A study of 200 pediatric inpatients ranging from 4 days to 15 years of age who received a gadolinium-based contrast agent reported no clinically adverse events, including among children who underwent multiple contrast-enhanced exams.²⁰ Even so, non-contrast MRA is generally preferred in children whenever it can answer the clinical question, both to avoid any theoretical risk from gadolinium and because placing an IV in a small child adds stress to the experience.

During pregnancy, gadolinium crosses the placenta and reaches the fetus, which is why most guidelines recommend avoiding it unless the benefit clearly outweighs the risk. Non-contrast MRA and non-contrast MRI are considered safe during pregnancy and are used when imaging is needed. During lactation the picture shifts: the amount of gadolinium that enters breast milk is very small, and professional societies generally consider it safe to continue breastfeeding after a contrast-enhanced MRI without needing to pump and dump. If you are pregnant or breastfeeding and an MRA has been recommended, talking through the contrast decision with your radiologist is well worth the extra few minutes.

What to Expect on the Day of Your Scan

Whether or not contrast is involved, an MRA scan feels much like a standard MRI. You will lie on a table that slides into a large tube, and the machine will make loud knocking and buzzing sounds for anywhere from 20 minutes to over an hour depending on which body region is being scanned. You will be given earplugs or headphones. Metal jewelry, watches, and clothing with metal fasteners need to come off. If you have any implanted metal devices, tell the scheduling team in advance since some are not MRI-compatible.

If your study calls for contrast, a small IV line will be placed in your hand or forearm before the scan begins. The gadolinium injection itself takes only a few seconds. Some people feel a brief cool sensation at the injection site or a metallic taste in the mouth, both of which pass quickly. After the scan, the IV is removed and you can usually resume normal activities immediately. Drinking extra water in the hours after a contrast-enhanced MRA can help your kidneys clear the gadolinium a bit faster, though healthy kidneys will eliminate the vast majority of it within a day regardless.

If your scan is non-contrast, there is no IV, no injection, and no dietary restrictions. The entire process is noninvasive, which is part of what makes non-contrast MRA so appealing for routine vascular screening and for patients who will need many follow-up scans over the years. Either way, the images your radiologist reviews will be detailed cross-sectional maps of your blood vessels, often reconstructed into three-dimensional models that can be rotated and examined from any angle before your results are sent to the doctor who ordered the study.